about
Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFRA.Omenn syndrome--review of several phenotypes of Omenn syndrome and RAG1/RAG2 mutations in Japan.Detection of ATM gene mutation in human glioma cell line M059J by a rapid frameshift/stop codon assay in yeast.Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.Pediatric intestinal Behçet disease complicated by myeloid malignancies.Congenital Glioblastoma with Distinct Clinical and Molecular Characteristics: Case Reports and a Literature Review.Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome.Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols.High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.Long-term parvovirus B19 infections with genetic drift after cord blood transplantation complicated by persistent CD4+ lymphocytopenia.EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.RUNX1 mutation associated with clonal evolution in relapsed pediatric acute myeloid leukemia with t(16;21)(p11;q22).Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen.Successful clinical response to irinotecan in relapsed neuroblastoma.IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia.CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.Cytomegalovirus retinitis during maintenance therapy for T-cell acute lymphoblastic leukemia.Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy.Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.Germline IKAROS mutation associated with primary immunodeficiency that progressed to T-cell acute lymphoblastic leukemia.Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia.JAK2, MPL, and CALR mutations in children with essential thrombocythemia.Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.Incidence, clinical features, and risk factors of idiopathic pneumonia syndrome following hematopoietic stem cell transplantation in children.Transient myeloproliferative disorder with partial trisomy 21.Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma.Relapsed childhood acute myeloid leukemia patient with inversion of chromosome 16 harboring a low FLT3 internal tandem duplication allelic burden and KIT mutations.Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases.DNMT3A mutations are rare in childhood acute myeloid leukaemia, myelodysplastic syndromes and juvenile myelomonocytic leukaemia.Hemophagocytic lymphohistiocytosis associated with uncontrolled inflammatory cytokinemia and chemokinemia was caused by systemic anaplastic large cell lymphoma: a case report and review of the literature.Suspected early onset of congenital Langerhans cell histiocytosis involving ectopic cervical thymus and mediastinal thymus, simultaneously.
P50
Q36314224-5E95BE04-BD18-44AC-8DD3-BE79E384476FQ36639621-41100538-7A2F-40C2-97D4-EB234C1D2E22Q38287358-430F2092-9C11-4687-B61F-C99F26FAC3D9Q38435146-F3F52343-59B4-4D2D-ACE9-3394667923F5Q39009800-EB499D09-F15B-49A8-BBB2-F1257BFFD81EQ39142172-8DA13151-A6D9-4BE2-A1FD-71FB86D6900FQ40381532-3797F4DC-D83C-415F-AD5A-F0D6D40E2AAFQ40513597-D31A29AD-3550-4D82-BF33-DE30FB9DE841Q40735293-66F98BDA-1F21-445A-A062-1BE5C15C1300Q40781300-0AFE0B8E-594E-4F3A-85F4-7B4A8E02E2E1Q41036515-17C0FA87-50A9-42CA-8D94-21212700931BQ41203406-8E290D78-E7C4-4D1D-B4AD-871972CF5D9EQ42246346-3B63EAC6-63A1-49DC-8DCA-EAE57296E286Q42979885-6253E71A-701C-473C-ACF8-820B773B664FQ43457342-11413C73-9AF3-42FA-914F-BCD51B8956B3Q43819705-C53E42AF-7DBD-44B4-9F45-F20EE9814083Q44236080-A672D7B2-FDBD-4B61-A86E-897792BACDD6Q45326639-29D7B760-0008-4BBB-82C9-0DF6A48451AFQ45366674-5BCB1ED4-1655-4317-AA1F-9B67B6FD28B1Q45715491-D3A3ED66-259D-4E67-95A2-554F530E1471Q47119906-177FC87E-C653-4B03-B55A-5B17460089E6Q47805959-BC6F84AE-CFB3-4843-9BD8-B4E47DAC410AQ48188218-0DAA0D7F-AB2D-4D6C-9BEB-51F1CD97D06FQ48230865-45FE96D3-D7E5-4F7E-AF12-55C5CEEDE6C3Q48250287-006BB6C7-F60A-4A2E-8739-1CD40B06BF3AQ48343515-05B00C30-8CB8-4C06-AB4C-926398D1DEFFQ49848340-8ADAFB53-51CF-4252-9381-C294A6835493Q50239506-11196202-AC05-4276-8745-AD84D064F37AQ50454150-ADDFFD02-B55B-418C-9B09-25F480EE34A9Q50548714-D6C9BD26-0A87-449B-8724-1A6DB9315F0BQ51008175-BA8C1777-A480-4AB5-9E6E-22EFF6BB3CC4Q51009868-99FA261F-5EF6-48C8-9CF2-13E18AFAF6C3Q51067119-265EBF23-15EF-4E9B-BD2C-7981D6F3706DQ51169443-4266EA4F-0977-4935-91E2-572CE164BE15Q51615201-201A40B5-B872-4395-B0E7-61C0C3D8D68DQ52760255-7B9DFE3E-A099-4CA7-A65F-A83970D2CC6BQ53061326-B9727C53-7B38-4091-89E2-88B5403670D5Q53403193-402455E1-0E56-4238-A016-92E5A79FC9BFQ53523970-AE94263A-2570-4423-ADDB-C40BFA3FF2ABQ53569674-0513AEC0-2857-44C3-9319-56C1ABFC8FA2
P50
description
researcher ORCID ID = 0000-0001-5207-3779
@en
wetenschapper
@nl
name
Akira Shimada
@ast
Akira Shimada
@en
Akira Shimada
@es
Akira Shimada
@nl
type
label
Akira Shimada
@ast
Akira Shimada
@en
Akira Shimada
@es
Akira Shimada
@nl
prefLabel
Akira Shimada
@ast
Akira Shimada
@en
Akira Shimada
@es
Akira Shimada
@nl
P106
P1153
55176720800
P31
P496
0000-0001-5207-3779